written on 21.03.2014

Off-label Avastin in AMD: the European Commission gets involved


The controversy over the off-label use of Roche's Avastin (bevacizumab) in wet AMD has spread beyond national borders and is now on the EU agenda, after the European Commission said it was planning to launch a study of off-label prescribing to better…